公开(公告)号：US20150299193A1

公开(公告)日：2015-10-22

申请号：US14652024

申请日：2013-12-23

Applicant: CADILA HEALTHCARE LIMITED

Inventor： Ranjit C. Desai ,  Vrajesh Pandya ,  Pankaj Ramanbhai Patel

IPC: C07D471/04 ,  C07D409/04 ,  C07D401/12 ,  C07D215/58 ,  C07D417/12

CPC classification number: C07D471/04 ,  A61K31/4704 ,  C07D215/58 ,  C07D215/60 ,  C07D401/04 ,  C07D401/12 ,  C07D409/04 ,  C07D413/04 ,  C07D417/12 ,  C07D491/04 ,  C07D495/04 ,  C07D513/04

Abstract: The present invention relates to novel compounds of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation.

Abstract translation: 本发明涉及通式（I）的新化合物，其互变异构形式，其立体异构体，其药学上可接受的盐，含有它们的药物组合物，其制备方法，这些化合物在医药中的用途以及参与其制备的中间体 。

公开(公告)号：US20190100492A1

公开(公告)日：2019-04-04

申请号：US15992957

申请日：2018-05-30

Applicant: Cadila Healthcare Limited

Inventor： Dhiraj Gambhire ,  Rajendrakumar Hariprasad Jani ,  Bipin Pandey ,  Kaushik Sata ,  Himanshu Kothari ,  Pankaj Ramanbhai Patel

IPC: C07D207/333 ,  C07D207/33 ,  A61K45/06

Abstract: The present invention provides a therapeutic compound of formula (I) and their pharmaceutically acceptable salts for the prevention and treatment of lipodystrophy caused because of HIV infection or combination therapy of HIV-1 protease inhibitors (PIs) and/or reverse transcriptase inhibitors (nRTIs) by neutralizing lipohypertrophy, lipoatrophy and metabolic abnormalities in HIV patient.

公开(公告)号：US20170088514A1

公开(公告)日：2017-03-30

申请号：US15345035

申请日：2016-11-07

Applicant: Cadila Healthcare Limited

Inventor： Dhiraj Gambhire ,  Rajendrakumar Hariprasad Jani ,  Bipin Pandey ,  Kaushik Sata ,  Himanshu Kothari ,  Pankaj Ramanbhai Patel

IPC: C07D207/33

CPC classification number: C07D207/333 ,  A61K9/2009 ,  A61K9/2013 ,  A61K31/40 ,  A61K45/06 ,  C07D207/33

Abstract: The present invention provides a therapeutic compound of formula (I) and their pharmaceutically acceptable salts for the prevention and treatment of lipodystrophy caused because of HIV infection or combination therapy of HIV-1 protease inhibitors (PIs) and/or reverse transcriptase inhibitors (nRTIs) by neutralizing lipohypertrophy, lipoatrophy and metabolic abnormalities in HIV patient.

公开(公告)号：US09394300B2

公开(公告)日：2016-07-19

申请号：US14652024

申请日：2013-12-23

Applicant: Cadila Healthcare Limited

Inventor： Ranjit C. Desai ,  Vrajesh Pandya ,  Pankaj Ramanbhai Patel

IPC: C07D215/58 ,  A61K31/4704 ,  C07D471/04 ,  C07D215/60 ,  C07D401/04 ,  C07D401/12 ,  C07D413/04 ,  C07D417/12 ,  C07D491/04 ,  C07D495/04 ,  C07D513/04 ,  C07D409/04

CPC classification number: C07D471/04 ,  A61K31/4704 ,  C07D215/58 ,  C07D215/60 ,  C07D401/04 ,  C07D401/12 ,  C07D409/04 ,  C07D413/04 ,  C07D417/12 ,  C07D491/04 ,  C07D495/04 ,  C07D513/04

Abstract: The present invention relates to novel compounds of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation.

Abstract translation: 本发明涉及通式（I）的新化合物，其互变异构形式，其立体异构体，其药学上可接受的盐，含有它们的药物组合物，其制备方法，这些化合物在医药中的用途以及参与其制备的中间体 。